Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugate therapies for oncology indications. The company became publicly traded following its business combination with Ignyte Acquisition Corp, a SPAC that completed its IPO in 2021, with the merger closing in 2023. On March 5, 2024, Peak Bio filed an 8-K current report with the SEC under accession number 0001193125-24-059366, reflecting ongoing public-company disclosure obligations in the biotechnology and life sciences sector. As a post-combination entity, PKBO continues to operate under Nasdaq reporting requirements. For full filing details, sponsor history, and deal analytics on Peak Bio and hundreds of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.